The Lead Episode 159: A Discussion of Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid Cardiomyopathy and Sinus Rhythm

Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Prashanthan Sanders, MBBS, PhD, FHRS, about the journal article, Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid Cardiomyopathy and Sinus Rhythm. Together, they discuss the study findings and explore the relationship between atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy who are in sinus rhythm.

Learning Objectives:

• Review the key findings of the study examining atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy and sinus rhythm.
• Discuss the association between atrial mechanical contraction and cerebrovascular risk in this patient population.
• Explore the potential clinical implications of assessing atrial mechanical function in patients with transthyretin amyloid cardiomyopathy.

Host: Michael S. Lloyd, MD, FHRS

Guests:

Tina Baykaner, MD, MPH

Prashanthan Sanders, MBBS, PhD, FHRS

Disclosures:

M. Lloyd

• Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other

T. Baykaner

• Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific
• Research: NIH, Boston Scientific

P. Sanders

• Honoraria/Speaking/Consulting Fee: Boston Scientific, Abbott Medical
• Other Financial Relationships: Medtronic PLC, Pacemate, CathRx
• Research: Abbott, Becton Dickinson, Calyan Technologies, Ceryx Medical, Biosense Webster, CathRx, HelloAlfred, Medtronic, Inc., Abbott Medical